AG
ABUS icon

Algert Global’s Arbutus Biopharma ABUS Stock Holding History

Algert Global’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22,375
Closed -$211K – 368
2018
Q3 		$211K Sell
22,375
-12,441
-36% -$124K 0.05% 321
2018
Q2 		$254K Buy
+34,816
New +$207K 0.05% 296

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's ABUS Position: Q4 2018 in Review

Algert Global sold out of Arbutus Biopharma (ABUS) in Q4 2018, closing a stake of 22,375 shares — an estimated $211K sold.

Algert Global first reported a position in ABUS in Q2 2018 and held it in 2 quarters. The position peaked at $254K in Q2 2018. 71 funds tracked by Wall St. Rank hold ABUS as of Q4 2018.

  • Algert Global reported no remaining Arbutus Biopharma position as of Q4 2018 after selling out during the quarter.
  • Algert Global sold 22,375 Arbutus Biopharma shares in Q4 2018, an estimated $211K.
  • Algert Global first reported a position in Arbutus Biopharma in Q2 2018 and held it in 2 quarters.
  • Algert Global's Arbutus Biopharma position peaked at $254K in Q2 2018.
  • 71 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2018.

Based on Algert Global's 13F filing for Q4 2018, filed 1 Feb 2019.